AbbVie North Chicago plant has second fire

A fireman holding a firehose that is open and expelling water

An AbbVie ($ABBV) manufacturing facility in North Chicago had a fire in a laboratory this week. The origin of the blaze was believed to be electrical but AbbVie is investigating since it is the second fire at the plant in two months.

The firefighters were called in Tuesday night after a fire started in a laboratory and electronics storage room of the contract manufacturing plant, according to the Chicago Tribune. The blaze was contained to the room.

No one was hurt, Fire Chief Dell Urban told the newspaper. “The fire was held in check by the sprinkler system. Everyone had been evacuated and there were no injuries," Urban was quoted as saying.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Urban said there had been another fire recently, also contained by the sprinkler system. According to a couple of online reports, there was a fire at the plant April 4.

An AbbVie spokeswoman in an email would only confirm there was a fire and that there were no injuries and that production at the facility was unaffected.

While uncommon, fires do happen at pharma manufacturing facilities. Amgen ($AMGN) had two explosions and fires that injured people 9 months apart in May 2013 and January 2014 at Amgen's South San Francisco lab facility. It received a citation from the California OSHA.

- read the Chicago Tribune story

Related Articles:
Amgen facility has its second explosion in 9 months
Worker hurt in 'flash fire' at Amgen facility


Suggested Articles

Neopharma, which has been buying and building plants for several years, is buying a sterile injectables plant and assets in Japan from India’s Lupin. 

Already knocked by the FDA four times this year, Dr. Reddy’s now has a fifth Form 483 to dwell on. This time it’s at a plant with a history of faults.

In a warning letter, the FDA details how a Chinese OTC drugmaker handed over documents faked just for the agency's inspection—and admitted it.